following a full submission
rosuvastatin (Crestor®) is not recommended for use within NHS Scotland.
Indication under review: Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event as an adjunct to correction of other risk factors.
In a randomised, placebo-controlled, double-blind, multi-centre study, treatment with rosuvastatin was associated with a significantly reduced risk of first cardiovascular event versus placebo in patient sub-groups deemed to be high-risk when assessed using the Framingham equation and the SCORE algorithm.
The submitting company did not present sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice283KB (PDF)
- Medicine name:
- rosuvastatin (Crestor)
- SMC ID:
- For the prevention of major cardiovascular events in patients estimated to have a high risk for a first cardiovascular event.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Not recommended
- Date advice published
- 10 October 2011